Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](GW Pharmaceuticals Ltd.)"
Count: 50
Selected: 0
| NCT ID | Title |
|---|
| NCT01424566 | A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer | ||
| NCT01361607 | Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer | ||
| NCT01337089 | Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain | ||
| NCT01262651 | Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer | ||
| NCT04984278 | Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis | ||
| NCT04657666 | Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis | ||
| NCT04592159 | Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder | ||
| NCT04203498 | Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis | ||
| NCT02432612 | A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer | ||
| NCT02325024 | A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function. | ||
| NCT02325011 | An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience. | ||
| NCT02240160 | A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects | ||
| NCT02073474 | An Observational Post-Marketing Safety Registry of Sativex® | ||
| NCT01975688 | A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis | ||
| NCT01964547 | A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients | ||
| NCT01887301 | Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients | ||
| NCT01610713 | An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis | ||
| NCT01610700 | An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients | ||
| NCT01610687 | A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis | ||
| NCT01606202 | A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury | ||
| NCT01606189 | A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain | ||
| NCT01606176 | A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin | ||
| NCT01606137 | A Study of the Long-term Safety of Sativex Use | ||
| NCT01604265 | A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis | ||
| NCT01599234 | A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis | ||
| NCT01323569 | Abuse Potential of Sativex | ||
| NCT01323465 | Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex | ||
| NCT01322464 | Study to Assess Food Effect on Sativex Bioavailability | ||
| NCT01322139 | Sativex Thorough QT/QTc Study | ||
| NCT00713817 | A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain | ||
| NCT00713323 | A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain. | ||
| NCT00711880 | A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia. | ||
| NCT00711646 | A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis. | ||
| NCT00710554 | A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia | ||
| NCT00710424 | A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy | ||
| NCT00702468 | Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis | ||
| NCT00681538 | A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS) | ||
| NCT00678795 | A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis | ||
| NCT00675948 | Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain | ||
| NCT00674609 | A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy | ||
| NCT00530764 | A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. | ||
| NCT00391079 | Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS | ||
| NCT02660255 | Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy | ||
| NCT02283281 | Anesthetic Premedication With a Cannabis Extract (Cannapremed) | ||
| NCT01502046 | Neuroprotection by Cannabinoids in Huntington's Disease | ||
| NCT04447846 | Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome | ||
| NCT02332655 | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | ||
| NCT03848481 | CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) | ||
| NCT03202303 | Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) | ||
| NCT04423341 | Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm |
